» Articles » PMID: 2757911

Effects of Vigabatrin on Evoked Potentials in Epileptic Patients

Overview
Specialty Pharmacology
Date 1989 Jan 1
PMID 2757911
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

1. Somatosensory (SEP) brainstem auditory (BAEP) and visual (VEP) evoked potentials were determined before and after add-on administration of vigabatrin (GVG) in patients with epilepsy. 2. At pre-treatment assessment SEP and BAEP parameters were usually found to be within normal limits, while P100 latencies of the VEP were abnormally prolonged in a considerable proportion of patients. 3. In a double-blind, placebo-controlled trial in 22 patients GVG (1-3 g day-1 stratified according to body weight) given for 7 weeks did not modify any of the evoked potential parameters evaluated. 4. Eighteen patients were evaluated prospectively at regular intervals during long-term GVG (2-4 g day-1) therapy with a mean follow up of 24 months (range 13-42 months). SEP, BAEP and especially VEP parameters showed some interindividual variability, but the within patient variation was relatively small. No consistent important changes were seen in association with GVG, although a possible trend towards a shortening of BAEP latencies and P100 latencies was observed. 5. The relevance of these findings with respect to GVG safety is discussed.

Citing Articles

Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.

Kjellstrom U, Lovestam-Adrian M, Andreasson S, Ponjavic V Doc Ophthalmol. 2008; 117(2):93-101.

PMID: 18188629 DOI: 10.1007/s10633-007-9108-3.


Examining visual field defects in the paediatric population exposed to vigabatrin.

Spencer E, Harding G Doc Ophthalmol. 2004; 107(3):281-7.

PMID: 14711160 DOI: 10.1023/b:doop.0000005337.39947.83.


Vigabatrin; its effect on the electrophysiology of vision.

Harding G, Robertson K, Spencer E, Holliday I Doc Ophthalmol. 2002; 104(2):213-29.

PMID: 11999628 DOI: 10.1023/a:1014643528474.


Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.

Ponjavic V, Andreasson S Doc Ophthalmol. 2001; 102(1):63-72.

PMID: 11475366 DOI: 10.1023/a:1017589301855.


A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.

Srinivasan J, Richens A Drug Saf. 1994; 10(5):395-405.

PMID: 8037889 DOI: 10.2165/00002018-199410050-00004.


References
1.
Yiannikas C, Walsh J, McLeod J . Visual evoked potentials in the detection of subclinical optic toxic effects secondary to ethambutol. Arch Neurol. 1983; 40(10):645-8. DOI: 10.1001/archneur.1983.04050090081014. View

2.
Hammond E, Wilder B . Gamma-vinyl GABA: a new antiepileptic drug. Clin Neuropharmacol. 1985; 8(1):1-12. DOI: 10.1097/00002826-198503000-00001. View

3.
Stockard J, Iragui V . Clinically useful applications of evoked potentials in adult neurology. J Clin Neurophysiol. 1984; 1(2):159-202. DOI: 10.1097/00004691-198404000-00003. View

4.
Hammond E, Wilder B . Effect of gamma-vinyl GABA on human pattern evoked visual potentials. Neurology. 1985; 35(12):1801-3. DOI: 10.1212/wnl.35.12.1801. View

5.
Olivieri N, Buncic J, Chew E, Gallant T, Harrison R, Keenan N . Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986; 314(14):869-73. DOI: 10.1056/NEJM198604033141402. View